Trevi Therapeutics, Inc. (NASDAQ: TRVI)

Trevi Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio oral nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis interstitial lung disease other than IPF and refractory cough.

Trevi Therapeutics Inc currently does not have an approved product on the market and therefore does not generate revenue from product sales; the company is in the development stage and relies on external financing to support its research and clinical programs.

Trevi Therapeutics Inc operates in a competitive biopharmaceutical landscape where several companies are pursuing therapies for chronic cough associated with interstitial lung diseases and refractory cough.

Trevi Therapeutics Inc faces competition from other drug developers targeting similar indications. In the IPF related chronic cough space a compound known as BI 1839100 a TRPA1 antagonist was being developed by Boehringer Ingelheim but its development was terminated in 2025. For refractory cough the company expects competition from agents such as gefapixant a P2X3 antagonist that has been withdrawn from FDA review and camlipixant another P2X3 antagonist under development by GSK as well as taplucainium a charged sodium channel blocker being studied by Nocion Therapeutics. Additionally broader classes of agents such as benzonatate opioids corticosteroids proton pump inhibitors and neuromodulators are used off label for cough and represent alternative therapeutic options. Trevi Therapeutics Inc believes its competitive advantage lies in the unique mechanism of Haduvio which acts as a kappa receptor agonist and a mu receptor antagonist reducing cough while limiting abuse potential associated with pure mu agonists. The oral extended release formulation also offers a convenient dosing regimen compared to injectable nalbuphine which has been used for pain for decades. These factors may help differentiate Haduvio in a crowded market.

Trevi Therapeutics Inc intends to treat patients suffering from chronic cough that arises from idiopathic pulmonary fibrosis interstitial lung disease other than IPF and refractory cough. The company plans to market Haduvio to pulmonologists who specialize in interstitial lung disease and to allergists who manage refractory cough patients. Additionally the company may target specialized interstitial lung disease centers of excellence and other respiratory care providers that serve these patient populations.